Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | EGFR | P00533 | 1/20 | 0.38 |
| ▸ | ESR1 | P03372 | 2/20 | 0.36 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.36 |
| ▸ | HSD17B1 | P14061 | 5/20 | 0.32 |
| ▸ | HSD17B2 | P37059 | 5/20 | 0.32 |
| ▸ | ALDH1A3 | P47895 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | KIF11 | P52732 | 1/20 | 0.31 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.31 |
| ▸ | CNR1 | P21554 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29786931 | 1.00 | ALDH1A1 (0.41) | ALDH1A1SMN1; SMN2EGFRESR1ESR2 | |
| SCHEMBL21793428 | 0.81 | EGFR (0.43) | ALDH1A1SMN1; SMN2EGFRESR1ESR2 | |
| SCHEMBL21774250 | 0.81 | ALDH1A1 (0.41) | ALDH1A1SMN1; SMN2EGFRESR1ESR2 | |
| SCHEMBL21774350 | 0.78 | EGFR (0.39) | ALDH1A1SMN1; SMN2EGFRESR1ESR2 | |
| SCHEMBL29786785 | 0.78 | EGFR (0.39) | ALDH1A1SMN1; SMN2EGFRESR1ESR2 | |
| SCHEMBL6852399 | 0.76 | ALDH1A1 (0.55) | ALDH1A1SMN1; SMN2ALDH1A3KDM4EPTGS2 | |
| SCHEMBL29786888 | 0.72 | ERN1 (0.47) | ALDH1A1SMN1; SMN2EGFRKDM4ERAB9A | |
| SCHEMBL21774367 | 0.72 | ERN1 (0.47) | ALDH1A1SMN1; SMN2EGFRKDM4ERAB9A | |
| SCHEMBL4841994 | 0.72 | CYP2A6 (0.37) | ALDH1A1ESR1ESR2ALDH1A3KDM4E | |
| SCHEMBL8594827 | 0.71 | ERN1 (0.54) | ALDH1A1SMN1; SMN2EGFRHSD17B1HSD17B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113613652-B | Benzimidazole compounds and their use in the treatment of alzheimer's disease or huntington's disease | 台湾卫生研究院 | 2022-08-23 | — | — | CN | disclosed |
| CN-113613652-A | Benzimidazole compounds and their use for treating alzheimer's disease or huntington's disease | 台湾卫生研究院 | 2021-11-05 | — | — | CN | disclosed |
| EP-3843724-A1 | BENZIMIDAZOLE COMPOUNDS AND USE THEREOF FOR TREATING ALZHEIMER'S DISEASE OR HUNTINGTON'S DISEASE | National Health Research Institutes (TW) | 2021-07-07 | — | — | EP | disclosed |
| US-10584120-B1 | Benzimidazole compounds and use thereof for treating Alzheimer's Disease or Huntington's Disease | NATIONAL HEALTH RESEARCH INSTITUTES (TW) | 2020-03-10 | — | — | US | disclosed |
| US-20200071312-A1 | BENZIMIDAZOLE COMPOUNDS AND USE THEREOF FOR TREATING ALZHEIMER'S DISEASE OR HUNTINGTON'S DISEASE | NATIONAL HEALTH RES INST (TW) | 2020-03-05 | — | — | US | disclosed |
| US-20200071312-A1 | BENZIMIDAZOLE COMPOUNDS AND USE THEREOF FOR TREATING ALZHEIMER'S DISEASE OR HUNTINGTON'S DISEASE | NATIONAL HEALTH RES INST (TW) | 2020-03-05 | — | — | US | disclosed |
| WO-2020047360-A1 | BENZIMIDAZOLE COMPOUNDS AND USE THEREOF FOR TREATING ALZHEIMER'S DISEASE OR HUNTINGTON'S DISEASE | NATIONAL HEALTH RESEARCH INSTITUTES (TW) | 2020-03-05 | — | — | WO | disclosed |
| WO-2020047360-A1 | BENZIMIDAZOLE COMPOUNDS AND USE THEREOF FOR TREATING ALZHEIMER'S DISEASE OR HUNTINGTON'S DISEASE | NATIONAL HEALTH RESEARCH INSTITUTES (TW) | 2020-03-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200071312-A1 | BENZIMIDAZOLE COMPOUNDS AND USE THEREOF FOR TREATING ALZHEIMER'S DISEASE OR HUNTINGTON'S DISEASE | GLUL, GLS2, GLS | ALDH1A1 925/4885SMN1; SMN2 1261/4885EGFR 3299/4885 |
| US-10584120-B1 | Benzimidazole compounds and use thereof for treating Alzheimer's Disease or Huntington's Disease | GLUL, GLS2, GLS | ALDH1A1 925/4885SMN1; SMN2 1261/4885EGFR 3299/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.